Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company

6 February 2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal Soriot who commented on the firm’s year-end results at a media briefing in London this morning.

Mr Soriot (pictured above) emphasized the company’s focus on ‘rebuilding growth’ and investing in its pipeline in 2013, saying: “We gained momentum. We are working on growth, which starts with rebuilding our pipeline. It’s clear that we have made real progress in this area.”

He said the focus in 2014 will be to continue to advance its late stage pipeline in three core therapy areas of oncology, respiratory/inflammation and autoimmune (RIA) and cardio-vascular/metabolism (CVMD). The ultimate aim is for 2017 revenues to be in line with 2013 revenues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK